Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?

Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at ...

Recursion’s Incoming CEO Needs To Prove That AI Drug Development Can Pay Off

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week.
STAT

Recursion’s incoming CEO: Beyond hype on AI-driven drug development, it’s time to show results

In a Q&A, Recursion’s incoming CEO acknowledges hype around the idea of using AI to expedite drug development, and says it's ...

Is Recursion Pharmaceuticals a Meme Stock?

Is that the case? Let's look into it and decide whether the company is worth investing in.
STAT

Recursion seeks to deliver results, and a VC sees a wave of M&A coming

This week, my colleagues and I scheduled 30 minutes to talk with Mark Cuban for “The Readout LOUD” podcast. The conversation ...
pharmaphorum

Recursion, Exscientia, and AI drug discovery’s moment of truth

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
pharmaphorum

AI biotechs Exscientia and Recursion agree $688m merger

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...